154 related articles for article (PubMed ID: 38171533)
1. Intrahepatic cholangiocarcinoma: histological diversity and the role of the pathologist.
Komuta M
J Liver Cancer; 2024 Mar; 24(1):17-22. PubMed ID: 38171533
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
3. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
Sasaki M; Sato Y; Nakanuma Y
Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
[TBL] [Abstract][Full Text] [Related]
4. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.
Kinzler MN; Schulze F; Jeroch J; Schmitt C; Ebner S; Gretser S; Bein J; Finkelmeier F; Trojan J; Zeuzem S; Schnitzbauer AA; Demes MC; Reis H; Wild PJ; Walter D
Histopathology; 2024 May; 84(6):1061-1067. PubMed ID: 38409827
[TBL] [Abstract][Full Text] [Related]
6. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968
[TBL] [Abstract][Full Text] [Related]
8. Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologist's Role.
Komuta M
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201284
[TBL] [Abstract][Full Text] [Related]
9. Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.
Chung T; Rhee H; Shim HS; Yoo JE; Choi GH; Kim H; Park YN
Gut Liver; 2022 Jul; 16(4):613-624. PubMed ID: 34810298
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.
Sirica AE; Strazzabosco M; Cadamuro M
Adv Cancer Res; 2021; 149():321-387. PubMed ID: 33579427
[TBL] [Abstract][Full Text] [Related]
11. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
[TBL] [Abstract][Full Text] [Related]
12. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.
Madoff DC; Abi-Jaoudeh N; Braxton D; Goyal L; Jain D; Odisio BC; Salem R; Schattner M; Sheth R; Li D
Oncologist; 2022 Oct; 27(10):884-891. PubMed ID: 35925597
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
14. Molecular diagnosis of intrahepatic cholangiocarcinoma.
Haga H; Patel T
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):114-23. PubMed ID: 25267595
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
[TBL] [Abstract][Full Text] [Related]
16. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.
Rhee H; Kim MJ; Park YN; An C
Eur Radiol; 2019 Jun; 29(6):3111-3121. PubMed ID: 30560357
[TBL] [Abstract][Full Text] [Related]
17. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2023 Aug; 83(2):298-309. PubMed ID: 37140546
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of sarcomatoid change in patients with intrahepatic cholangiocarcinoma and prognosis after surgical liver resection: A Propensity Score Matching analysis.
Wang T; Kong J; Yang X; Shen S; Zhang M; Wang W
J Surg Oncol; 2020 Mar; 121(3):524-537. PubMed ID: 31867746
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma.
Sposito C; Ratti F; Cucchetti A; Ardito F; Ruzzenente A; Di Sandro S; Maspero M; Ercolani G; Di Benedetto F; Guglielmi A; Giuliante F; Aldrighetti L; Mazzaferro V
J Hepatol; 2023 Feb; 78(2):356-363. PubMed ID: 36328332
[TBL] [Abstract][Full Text] [Related]
20. Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review.
Akita M; Yanagimoto H; Tsugawa D; Zen Y; Fukumoto T
Surg Today; 2024 Apr; ():. PubMed ID: 38563999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
